argenex SE (NASDAQ:ARGX) Receives $1,016.22 Average Price Target from Brokerages

argenex SE (NASDAQ:ARGX) has earned a consensus rating of “Moderate Buy” from the twenty-four analysts that are presently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation, eighteen have given a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $1,017.7778.

Several research analysts have recently commented on ARGX shares. Oppenheimer decreased their target price on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a research report on Thursday, April 2nd. Zacks Research upgraded argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Robert W. Baird lifted their target price on argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a research report on Friday, February 27th. Wedbush reiterated an “outperform” rating and issued a $1,000.00 target price on shares of argenex in a research report on Monday, March 9th. Finally, Royal Bank Of Canada decreased their target price on argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a research report on Friday, February 27th.

argenex Stock Up 4.0%

Shares of NASDAQ ARGX opened at $813.28 on Thursday. The business has a 50 day moving average price of $755.99 and a two-hundred day moving average price of $816.91. argenex has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The firm has a market cap of $50.58 billion, a PE ratio of 36.21, a price-to-earnings-growth ratio of 1.31 and a beta of 0.46.

argenex (NASDAQ:ARGX) last issued its earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. The company had revenue of $1.31 billion during the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%. On average, analysts anticipate that argenex will post 23.96 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC lifted its holdings in shares of argenex by 32.1% in the 1st quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock worth $297,000 after purchasing an additional 122 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in shares of argenex by 5,962.5% in the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after purchasing an additional 1,431 shares during the last quarter. Focus Partners Wealth lifted its holdings in shares of argenex by 22.3% in the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after purchasing an additional 73 shares during the last quarter. Geneos Wealth Management Inc. lifted its holdings in shares of argenex by 550.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after purchasing an additional 99 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of argenex by 60.2% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock worth $73,000 after purchasing an additional 50 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.